Sanofi
Polypeptides comprising immunoglobulin single variable domains targeting TNFA and IL-23

Abstract:

The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF.alpha. and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.